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Abstract
Cerebral spinal fluid (CSF) and structural imaging markers are suggested as biomarkers amended to existing diagnostic
criteria of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). But there is no clear instruction on which markers
should be used at which stage of dementia. This study aimed to first investigate associations of the CSF markers as well as
volumes and shapes of the hippocampus and lateral ventricles with MCI and AD at the baseline and secondly apply these
baseline markers to predict MCI conversion in a two-year time using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
cohort. Our results suggested that the CSF markers, including Ab42, t-tau, and p-tau, distinguished MCI or AD from NC,
while the Ab42 CSF marker contributed to the differentiation between MCI and AD. The hippocampal shapes performed
better than the hippocampal volumes in classifying NC and MCI, NC and AD, as well as MCI and AD. Interestingly, the
ventricular volumes were better than the ventricular shapes to distinguish MCI or AD from NC, while the ventricular shapes
showed better accuracy than the ventricular volumes in classifying MCI and AD. As the CSF markers and the structural
markers are complementary, the combination of them showed great improvements in the classification accuracies of MCI
and AD. Moreover, the combination of these markers showed high sensitivity but low specificity for predicting conversion
from MCI to AD in two years. Hence, it is feasible to employ a cross-sectional sample to investigate dynamic associations of
the CSF and imaging markers with MCI and AD and to predict future MCI conversion. In particular, the volumetric
information may be good for the early stage of AD, while morphological shapes should be considered as markers in the
prediction of MCI conversion to AD together with the CSF markers.
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Introduction
Cerebral spinal fluid (CSF) and imaging markers have been
suggested as biomarkers to augment existing diagnostic criteria of
both mild cognitive impairment (MCI) and Alzheimer’s disease
(AD) [1,2,3,4,5,6]. Jack et al. [7] proposed a possible hypothetical
model in which biomarkers were temporally arranged in order of
abnormality along the pathological cascade of AD. In this model,
abnormal CSF Ab42 could occur two decades before the first
dementia-related symptoms, reaching a plateau prior any mani-
festation of cognitive impairment. In comparison to trajectories of
CSF tau, magnetic resonance imaging (MRI) markers surfaced
much later and were well correlated with the severity of AD
symptoms. However, this hypothetical model was directly derived
from longitudinal studies, where statistical inferences were founded
primarily on the rate of change of AD-related biomarkers over
time. For instance, increased rates of ventricular expansion and
brain atrophy in the medial temporal lobe were found to be
significantly correlated with cognitive decline, with good predic-
tions for MCI to AD conversion [8] [9] [10].
Beyond simple volumetric measures, morphological shape of the
brain captures not only the degree of tissue loss but also its precise
anatomical location. As such, brain shape measures have since
been suggested as improved predictors for MCI conversion to AD.
For instance, changes of hippocampal shapes between baseline
and a 2-year follow-up predicted MCI-AD conversion up to 80%
accuracy [11,12]. Unfortunately, to date, no clear, authoritative
instruction on which structural MRI measures are to be associated
with MCI and AD is available. This could be, partly, a result of the
extensive variety of image analysis techniques available. In
addition, while recent studies [13,14] have tested the feasibility
of baseline structural volumes and CSF in predicting conversion
from MCI to AD, performance of baseline structural shapes with
CSF markers for MCI-AD conversion remains relatively un-
known.
In this paper, we first evaluated the hypothetical model
suggested by Jack et al. [7] through a cross-sectional study on
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.
For this, we employed a supervised, multivariate classification
method, support vector machine (SVM), to distinguish MCI and
AD from normal aging. Features used include CSF biomarkers
and the shapes and volumes of hippocampus and lateral ventricles.
The hippocampi and lateral ventricles were chosen for their well-
validated status as prominent hallmarks of AD
[8,15,16,17,18,19,20]. Subsequently, we aim to predict MCI
conversion to AD over a two-year follow-up period using baseline
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CSF and MRI measures. In particular, both volumetric and shape
analyses were applied to compare their sensitivity and specificity in
the prediction of MCI conversion to AD.
Methods
The ADNI was launched in 2003 by the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration [21],
private pharmaceutical companies and non-profit organizations,
as a $60 million, 5-year public–private partnership. The primary
goal of ADNI has been to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological assess-
ments can be combined to measure the progression of MCI and
early AD. Determination of sensitive and specific markers of very
early AD progression is intended to aid researchers and clinicians
to develop new treatments and monitor their effectiveness, as well
as lessen the time and cost of clinical trials.
ADNI is the result of efforts of many coinvestigators from a
broad range of academic institutions and private corporations, and
subjects have been recruited from over 50 sites across the U.S. and
Canada. The initial goal of ADNI was to recruit 800 adults, ages
55 to 90, to participate in the research — approximately 200
cognitively normal older individuals to be followed for 3 years, 400
people with MCI to be followed for 3 years, and 200 people with
early AD to be followed for 2years (see www.adni-info.org for up-
to-date information). The data were analyzed anonymously, using
publicly available secondary data from the ADNI study, therefore
no ethics statement is required for this work.
Subjects
The ADNI general eligibility criteria are described at www.
adni- info.org. Briefly, subjects are between 55–90 years of age,
having a study partner able to provide an independent evaluation
of functioning. Specific psychoactive medications will be excluded.
General inclusion/exclusion criteria are as follows: 1) healthy
subjects: Mini- Mental State Examination (MMSE) scores between
24–30, a Clinical Dementia Rating (CDR) of 0, non-depressed,
non-MCI, and nondemented; 2) MCI subjects: MMSE scores
between 24–30, a memory complaint, having objective memory
loss measured by education adjusted scores on Wechsler Memory
Scale Logical Memory II, a CDR of 0.5, absence of significant
levels of impairment in other cognitive domains, essentially
preserved activities of daily living, and an absence of dementia;
and 3) mild AD: MMSE scores between 20–26, CDR of 0.5 or 1.0,
and meets the National Institute of Neurological and Communi-
cative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS/ADRDA) criteria for
probable AD.
In this study, 383 subjects were chosen from our previous study
[22]. Within this group, 218 have both MRI and CSF baseline
data (age: 74.467.2 years), with 72 normal controls (NC), 35 AD
subjects, and 111 MCI patients. Amongst these 383 subjects, 25
subjects with MCI converted to AD within 24 months.
Structural MR scans were collected across a variety of scanners
with protocols individualized for each scanner, as defined at www.
loni.ucla.edu/ADNI/Research/Cores/index.shtml. The CSF
Ab42, t-tau and p-tau data were downloaded from the ADNI
web site (www.loni.ucla.edu/ADNI).
MRI analysis
Figure 1 illustrates the MRI data processing that is detailed
below.
Structural Delineation. We automatically delineated the
hippocampus (HC) and lateral ventricles (LV) from the intensity
inhomogeneity corrected T1-weighted MR images using Free-
Surfer [23]. Due to the lack of constraints on structural shapes, this
process introduced irregularities and topological errors (e.g. holes)
at the hippocampal and ventricular boundary. This would increase
shape variation and thus reduces statistical power to detect group
differences. To avoid this pitfall, we generated the hippocampal or
ventricular shape of each individual subject with the properties of
smoothness and correct topology by injecting an atlas shape into
them using the large deformation diffeomorphic metric image
mapping algorithm [24]. The hippocampal and lateral ventricular
atlas shapes were created from 41 manually labeled hippocampi
and lateral ventricles via a large deformation diffeomorphic atlas
generation algorithm [25]. Each hippocampal (or lateral ventric-
ular) volume was approximated by the transformed atlas through
the LDDMM transformation. The reader is referred to [26] for
the mathematical derivation of this atlas injection procedure and
its evaluation as well as the segmentation accuracy on the
hippocampus and lateral ventricles. This delineation approach has
been successfully applied to investigate the hippocampus and other
subcortical shapes in AD [22].
We constructed the surface representation of the hippocampus
and lateral ventricles by composing the LDDMM transformation
on the corresponding atlas surfaces [27]. The left and right
hippocampal surfaces were respectively constructed using 2364
triangles with 1184 vertices and 2458 triangles with 1231 vertices,
while the left and right lateral ventricular surfaces were
respectively composed of 6966 triangles with 3485 vertices and
7890 triangles with 3947 vertices. The average triangle area and
edge length of the hippocampal surfaces were respectively
0.59 mm2 and 1.2 mm, while those of the ventricular surfaces
were respectively 0.64 mm2 and 1.1 mm. Hence, the size of the
triangles was comparable to the image resolution (1 mm3).
ISOMAP Shape Embedding. Unlike the scalar volume
measure, structural shapes lie on a high dimensional space, which
makes it challenging for statistical inference. In this study, we
employed ISOMAP [28] to embed the shapes of the hippocampus
and lateral ventricles into a Euclidean space with a few dimensions
such that this low-dimensional embedding is quasi-isometric to the
shapes in the high dimensional space. For this, we first computed
diffeomorphic metric distances between any two shapes using their
first order approximation described in [29] and constructed a pair-
wise distance matrix. ISOMAP then found a Euclidean low-
dimensional representation of the shapes that preserved the
relationship of any two shapes described in the pair-wise distance
matrix. These Euclidean coordinates were obtained by finding
eigenvectors corresponding to the largest eigenvalues of the kernel
matrix stemmed from the distance matrix reshaped by a centering
matrix [28]. The dimension of the eigenvectors is the same as the
number of subjects, and each eigenvector is one component or one
dimension of the ISOMAP shape embedding. Using this approach
with all 383 subjects, the bilateral hippocampal shapes can be
characterized using the first 20 ISOMAP components whose
Euclidean distance matrix is highly correlated with the pair-wise
metric distance matrix generated using the first order approxima-
tion of the diffeomorphic metric (Pearson’s Correlation: r = 0.91).
The bilateral lateral ventricular shapes can be represented using
the first 20 ISOMAP components whose Euclidean distance
matrix is very much similar to the pair-wise metric distance matrix
(Pearson’s Correlation: r = 0.97).
CSF and Brain Shapes in MCI and AD
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Statistical Analysis
A linear support vector machine (SVM) [30] was employed to
identify diagnosis of subjects from any two groups (NC, MCI, and
AD). The SVM classifier seeks the optimal decision boundary that
has a maximal margin closest to the training samples such that
generalization error bound can be minimized. Hence, the SVM
classifier is robust to outliers. In our study, we independently and
jointly considered volumes (or shapes) of the hippocampus, lateral
ventricles and CSF markers as the SVM input features to identify
subjects with MCI and AD from NC and MCI from AD. Shape
features comprise only of ISOMAP components with significant
group differences based on Student t-tests.
Our study had fewer AD subjects as compared to the NC or
MCI groups. To resolve any influences of unequal sample sizes
among the NC, MCI, and AD groups on the classification
accuracy, we employed random sampling to reduce the number of
NC and MCI subjects such that all three groups have equal sample
sizes. This was repeated for 100 times. For each trial, leave-one-
out cross-validation was adopted to estimate the classification
accuracy. The confidence interval of the classification accuracy
was computed.
Moreover, we also applied the SVM to test the sensitivity and
specificity for predicting MCI conversion in a two-year time
window when volumes (or shapes) of the hippocampus and lateral
ventricles as well as CSF markers assessed at the baseline were
independently or jointly considered as features in the SVM.
Results
Demographic Information
Demographic information for different diagnosis groups at
baseline are shown in Table 1. No significant differences in age
were found among the NC, MCI, and AD groups (ANOVA,
p= 0.454). 25 out of 111 MCI subjects were diagnosed as AD at
the two-year follow up and were denoted as the MCI-c group.
Rest of the MCI subjects were placed in the MCI-s group. No
significant MMSE difference was found between the two MCI
groups at baseline (p = 0.10).
Markers at Stages of MCI an AD
Hippocampal volume and shape markers. Bilateral hip-
pocampal volumes distinguished MCI and AD subjects from
normal controls at an accuracy of 61.9% and 65.5% respectively,
with relatively high specificity (MCI: 66.1%; AD: 73.3%) but low
sensitivity (MCI: 57.7%; AD: 57.8%) (Table 2). However, the
hippocampal volumes lost statistical power in the separation of
subjects with MCI and AD (classification accuracy: 42.3%;
sensitivity: 45.3%; specificity: 39.2%, Table 2).
In shape analysis, the first 20 ISOMAP components character-
ized bilateral hippocampal shapes among all 383 subjects. The 1st,
2nd, 3rd, 4th, 9th, 13th, 18th components contributed to hippocam-
pal shape differences between NC and AD. Among these
components, most of them (the 1st, 2nd, 3rd, 7th, 13th) also
contributed to shape differences between NC and MCI (Table 3).
Interestingly, only the 4th and 9th components showed shape
differences between MCI and AD. Moreover, among these
ISOMAP components, the 1st and 2nd components were highly
correlated with the hippocampal volume (Pearson correlations:
r = 0.7, p,0.01 for the 1st component; r = 0.5, p,0.01 for the 2nd
component), which were dominant components for group
differences in hippocampal shapes between NC and MCI. This
is illustrated as relatively homogeneous shrinkage over the bilateral
hippocampi in Figure 2 (a,b). But the 4th and 9th components
were not associated with the hippocampal volume (p.0.05),
suggesting that only local hippocampal shapes contributed to the
difference between MCI and AD, as seen in Figure 2 (c,d). This
can be further supported by evidence of increased classification
accuracy rates for the classifications between NC and AD (79.2%),
NC and MCI (67.4%), and MCI and AD (57.2%) (Table 2) when
the ISOMAP embedding of hippocampal shapes were used in the
SVM classifiers.
Lateral ventricular volume and shape markers. The
volumes of bilateral lateral ventricles distinguished subjects with
MCI and AD from normal controls at the accuracy of 63.1% and
65.5% respectively, with relatively high specificity (MCI: 75.3%;
AD: 72.3%) but low sensitivity (MCI: 50.9%; AD: 58.8%)
(Table 2). However, volumes of the lateral ventricles lost statistical
Figure 1. Schematic of MRI data processing.
doi:10.1371/journal.pone.0047406.g001
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power in separating subjects with MCI and AD (classification
accuracy: 30.4%; sensitivity: 21.2%; specificity: 39.7%, Table 2).
In shape analysis, the first 20 ISOMAP components character-
ized bilateral lateral ventricular shapes among all 383 subjects.
The 1st, 7th, 8th, 9th, 17th, 19th components contributed to
hippocampal shape differences between NC and AD. Among
these components, several of them (the 1st, 8th) also contributed to
shape differences between NC and MCI (Table 3). Interestingly,
only the 9th, 13th, and 17th components showed the shape
differences between MCI and AD. Moreover, among these
ISOMAP components, the 1st component was highly correlated
with the ventricular volume (Pearson correlations: r = 0.98,
p,0.01), though it was not the only component contributing to
shape differences between NC and MCI, as illustrated in Figure 3
(a,b). However, the 9th, 13th, and 17th components were not
associated with the lateral ventricular volume (p.0.05), suggesting
that only local ventricular shapes contributed to the difference
between MCI and AD. This can also be seen in Figure 3 (c,d).
Unlike the hippocampus, the lateral ventricular shapes did not
lead to better classification accuracy rates between NC and AD
(61.5%), and between NC and MCI (59%) when compared with
the lateral ventricular volumes (see Table 2). However, the
ventricular shapes achieved markedly better accuracy in distin-
guishing MCI and AD (60.1%) (Table 2).
CSF Markers. Student’s t-tests revealed that all three CSF
markers, Ab42, t-tau, and p-tau, showed statistically significant
differences between NC and AD and between NC and MCI
(Table 3). However, only Ab42 showed group differences
between MCI and AD (Table 3). The SVM classification
revealed that the CSF markers can distinguish NC and AD at
the classification accuracy of 81.4%, higher than those based on
the hippocampal or ventricular imaging markers (Table 2).
Additionally, the CSF markers achieved similar accuracy in
distinguishing NC and MCI, and MCI and AD subjects in
comparison with hippocampal and ventricular shapes. Interest-
ingly, the CSF markers gave higher sensitivities than the imaging
markers (Table 2).
The combination of the Imaging and CSF
Markers. Combining the CSF markers and the volumes of
the hippocampus and lateral ventricles as features in the SVM
Table 1. Demographic information for each of the diagnosis groups (normal controls (NC), mild cognitive impairment (MCI), and
Alzheimer’s disease (AD)) at the baseline.
Group Subjects n Age (mean±SD) Gender (female/male) MMSE (mean±SD)
NC 72 75.265.2 35/37 2961
MCI-s 86 7467.7 28/58 26.761.8
MCI-c 25 73.566.9 6/19 26.161.5
AD 35 74.669.3 15/20 22.961.8
Note: SD – standard deviation; MMSE – mini-mental state examination; MCI-s – subjects with MCI who remained as MCI at the two-year follow up; MCI-c – subjects with
MCI who converted as AD at the two-year follow up.
doi:10.1371/journal.pone.0047406.t001
Table 2. The classification accuracy, sensitivity, and specificity of the support vector machine (SVM) classifiers are given for
distinguishing normal controls (NC) and subjects with Alzheimer’s disease (AD), NC and subjects with mild cognitive impairment
(MCI), and subjects with MCI and AD.
NC.vs. AD NC.vs. MCI MCI.vs. AD
Hippocampal Volumes and Shapes
Hp volumes 65.5% (CI: 64.4%,66.6%)
Sensitivity = 57.8%, Specificity = 73.3%
61.9% (CI: 61%,62.8%)
Sensitivity = 57.7%, Specificity = 66.1%
42.3% (CI:32.2%,52.3%)
Sensitivity = 45.3%, Specificity = 39.2%
Hp shapes 79.2% (CI: 78.5%,80%)
Sensitivity = 75.8%, Specificity = 82.8%
67.4% (CI: 66.2%,68.6%)
Sensitivity = 64%, Specificity = 70.8%
57.2% (CI: 51.7%,62.8%)
Sensitivity = 59.9%, Specificity = 54.5%
Lateral Ventricular Volumes and Shapes
LV volumes 65.5% (CI: 64.9%,66.1%)
Sensitivity = 58.8% Specificity = 72.3%
63.1% (CI: 62%,64.2%)
Sensitivity = 50.9%, Specificity = 75.3%
30.4% (CI: 18.8%,42%)
Sensitivity = 21.2% Specificity = 39.7%
LV shapes 61.5% (CI: 59.2%,63.9%)
Sensitivity = 59.2%, Specificity = 63.9%
59% (CI: 56.1%,62%)
Sensitivity = 53.6%, Specificity = 64.4%
60.1% (CI:57.1%,63.1%)
Sensitivity = 62%, Specificity = 58.3%
CSF
CSF markers 81.4% (CI: 80.3%,82.5%)
Sensitivity = 87.4%, Specificity = 74.9%
68.4% (CI: 67.8%,69%)
Sensitivity = 66.7%, Specificity = 70.1%
61.3% (CI: 59.4%,63.2%)





Sensitivity = 88.8%, Specificity = 82%
72% (CI: 70.5%,73.5%)
Sensitivity = 70.1%, Specificity = 73.9%
60.9% (CI: 59.1%,62.8%)




Sensitivity = 94.7%, Specificity = 89.8%
70.3% (CI: 68.6%,72.9%)
Sensitivity = 69.5%, specificity = 71.9%
69.6% (CI: 66.4%,72.8%)
Sensitivity = 70.7%, Specificity = 68.6%
The volumes and shapes of the hippocampus (Hp) and lateral ventricles (LV) as well as cerebral spinal fluid (CSF) markers are respectively used as features in the SVM.
doi:10.1371/journal.pone.0047406.t002
CSF and Brain Shapes in MCI and AD
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increased the classification accuracies between NC and AD
(85.4%) and between NC and MCI (72%) when compared to
those achieved using only one type of markers (see Table 2).
Nevertheless, there was no improvement on the classification
accuracy between MCI and AD when compared with that using
the CSF markers alone.
Combining the CSF markers and the shapes of the hippocam-
pus and lateral ventricles as features in the SVM increased the
classification accuracies between NC and AD (92.2%), between
NC and MCI (70.3%), and between MCI and AD (69.6%) when
compared to those achieved using only one type of the markers
(see Table 2).
Shapes of the two structures with the CSF markers performed
better in separating NC and MCI (p,0.001) or NC and AD
(p,0.001) when compared to features combining the volumes and
CSF markers. However, shapes of the two structures with the CSF
markers performed worse in separating NC and MCI when
compared to features combining the volumes and CSF markers
(p = 0.013).
Prediction of the MCI Conversion
To predict MCI conversion at a two-year follow-up, we trained
an NC and AD classifier using the CSF and imaging markers
before applying it to the 25 MCI converters and 86 MCI non-
converters. Again, combination of the CSF markers with the
hippocampus and lateral ventricles shapes at baseline showed the
best prediction (66.7%) and sensitivity (82%) for identifying the
MCI converters when compared to individual imaging or CSF
markers (Table 4).
Discussion
Our study demonstrated the dynamic trajectories of the CSF,
hippocampal and lateral ventricular markers in the Alzheimer’s
pathological cascade using a cross-sectional ADNI sample and also
showed the feasibility of predicting future MCI-to-AD conversion
using baseline CSF and imaging markers. The CSF markers,
including Ab42, t-tau, and p-tau, distinguished MCI or AD from
NC, while only the Ab42 CSF marker contributed to the
differentiation between MCI and AD. The hippocampal shapes
performed better than the hippocampal volumes in classifying NC
and MCI, NC and AD, as well as MCI and AD. Interestingly, as
compared to the ventricular shape, ventricular volume performed
better in distinguishing MCI or AD from NC. The ventricular
shape, however, showed better accuracy in the classification for
MCI and AD. As the CSF and structural markers were
complementary, their combination showed great improvement
in the classification accuracies at all the stages of AD. Moreover,
the combination of these baseline markers also showed high
sensitivity but low specificity for predicting MCI conversion to AD
during a two-year period.
Our findings supported the conclusion drawn in previous
studies [31]; [32], where abnormality of both CSF Ab42 and
neurodegenerative biomarkers, including CSF tau and MRI
markers, precedes clinical symptoms; all these markers showed
significant differences between NC and MCI groups. However,
our findings did not support the hypothesis where CSF Ab42
reaches a plateau before the appearance of MRI atrophy and
cognitive symptoms, and remain static thereafter [7]. In our study,
CSF Ab42 continued to show appreciable power discriminant
between MCI and AD. In contrast, CSF tau lost its discriminating
power in distinguishing MCI and AD patients, suggesting that
CSF Ab42 reaches its plateau after CSF tau in the Alzheimer’s
pathological cascade.
MCI and AD patients were not well-separated using hippo-
campal volume, implying that the overall tissue loss in the
hippocampus may not be a good marker for monitoring AD
progression. However, we may not conclude that the hippocampus
Figure 2. Hippocampal shape differences among normal
controls (NC), mild cognitive impairment (MCI), and Alzhei-
mer’s Disease (AD). Panels (a,b) respectively show group differences
in the left and right hippocampal surface deformations between MCI
and NC. Panels (c,d) respectively show group differences in the left and
right hippocampal surface deformations between AD and MCI. Warm
color denotes regions where structures have surface outward-defor-
mation in the former group when compared with the latter group,
while cool color denotes regions where structures have surface inward-
deformation in the former group when compared with the latter group.
doi:10.1371/journal.pone.0047406.g002
Table 3. ISOMAP components of the hippocampus and lateral ventricles as well as CSF markers contribute to the group
differences between normal controls (NC) and subjects with Alzheimer’s disease (AD), NC and subjects with mild cognitive
impairment (MCI), and subjects with MCI and AD.
NC.vs. AD NC.vs. MCI MCI vs AD
Imaging Markers
ISOMAP components ISOMAP components ISOMAP components
hippocampal shapes 1,2,3,4,9,13,18 1,2,3,7,13 4,9
lateral ventricular shapes 1,7,8,9,17,19 1,8,12,14 9, 13,17
CSF Markers
CSF Ab42, t-tau, p-tau Ab42, t-tau, p-tau Ab42, t-tau, p-tau Ab42
doi:10.1371/journal.pone.0047406.t003
CSF and Brain Shapes in MCI and AD
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reached its abnormality peak before the late stage of AD, as its
local shape variations were significantly associated with progres-
sion from MCI to AD. Our results also showed that such local
shape markers aided the hippocampal markers in achieving
slightly better accuracy than the CSF markers in the prediction for
MCI conversion to AD. This was also supported by previous
studies, suggesting that MRI markers (e.g. cortical thickness of the
medial temporal lobe) correlate well with severity of cognitive
impairment and have greater predictive power than the CSF tau
[33]. Based on these evidences, we may conclude that the
hippocampal shape marker reaches its plateau after CSF tau.
However, the order in which the CSF Ab42 and MRI markers
reach their abnormality peaks is still unclear based on our current
study.
The volume of the lateral ventricles cannot distinguish MCI and
AD patients. Interestingly, the overall expansion of the lateral
ventricles showed better performance in identifying MCI or AD
from NC when compared with their shapes. This result agrees
with previous studies, suggesting that rates of ventricular
expansion were significantly different between AD (or MCI) and
NC groups [8]. This implies that complicated shape analysis might
not always be necessary to provide better structural morphological
markers when compared to volumetric analysis. Even for the same
structure, its markers can be different at different stages of AD.
Again, we may not conclude that the lateral ventricles reached
their abnormality peak before the late stage of AD, as their local
shape variations were significantly associated with progression
from MCI to AD. Likewise, ventricular shape markers slightly
outperformed CSF markers in the prediction for MCI conversion
to AD, as verified by previous studies [34], wherein clearer
correlation was observed for ventricular volumes against worsen-
ing cognitive indices, as compared to CSF biomarkers.
Our study showed that the CSF and structural markers are
complementary to each other in the AD pathological cascade.
This suggests that the CSF markers, (Ab42, t-tau, and p-tau) with
the volumes of the hippocampus and lateral ventricles, is a good
combination for distinguishing NC and MCI, while CSF Ab42
marker with the shape of the hippocampus and lateral ventricles is
a good combination for identifying MCI and AD.
As the shapes of the hippocampus and lateral ventricles
contributed more to the difference between MCI and AD than
their volumes, our study further showed that the combination of
the CSF markers and the shapes of the two structures at baseline
predicted MCI conversion to AD in the two-year follow up at an
Figure 3. Shape differences of the lateral ventricles among normal controls (NC), mild cognitive impairment (MCI), and Alzheimer’s
Disease (AD). Panels (a,b) respectively show group differences in the left and right lateral ventricular surface deformations between MCI and NC.
Panels (c,d) respectively show group differences in the left and right lateral ventricular surface deformations between AD and MCI. Warm color
denotes regions where structures have surface outward-deformation in the former group when compared with the latter group, while cool color
denotes regions where structures have surface inward-deformation in the former group when compared with the latter group.
doi:10.1371/journal.pone.0047406.g003
Table 4. The accuracy, sensitivity, and specificity for predicting the MCI converters are listed when the volumes or shapes of the
hippocampus (Hp) or the lateral ventricles (LV), or the CSF markers, or their combination were used as features in the classification.
Markers Accuracy (95% CI) Sensitivity Specificity
Hippocampal volumes and Shapes
Hp volumes 54%(53.1%,54.9%) 54.4% 53.6%
Hp shapes 63%(62.1%,64%) 74.9% 51.2%
Lateral Ventricular Volumes and Shapes
LV volumes 55.6%(54.7%,56.5) 63.7% 47.5%
LV shapes 62.7%(61.5%,63.9%) 67.9% 57.5%
CSF
CSF markers 62.2%(61.3%,63.1%) 80.4% 44%
Combination
CSF, Hp volumes, LV volumes 59.2%(58.3%,60%) 81.1%(80.5%,81.6%) 37.2%(35.6%,38.9%)
CSF, Hp shapes, LV shapes 66.7%(65.7%,67.8%) 82%(81.5%,82.6%) 51.4% (49.4%,53.3%)
doi:10.1371/journal.pone.0047406.t004
CSF and Brain Shapes in MCI and AD
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e47406
improved accuracy of 66.7%. Previous studies [35] achieved
similar prediction accuracy (68.5%) for the MCI conversion within
a three-year follow up, with suggestions claiming that multiple
predictors, including the CSF markers, hippocampal volume,
entorhinal cortex thickness, etc. would not perform better than a
single predictor. This differs from the conclusion derived from our
findings, possibly because structural shape measures contain more
complementing features than structural volume measures. The
combination of the shapes and CSF markers achieved high
classification accuracy (92.2%) between NC and AD, improving
by more than 10% over the CSF markers. This result is
comparable to those previously reported where CSF, MRI and
PET imaging markers were combined [36].
In summary, we conclude that it is feasible to employ a cross-
sectional sample to investigate dynamic associations of the CSF
and imaging markers with MCI and AD and to predict future
MCI conversion to AD. In particular, volumetric information may
be good for the early stages of AD while morphological shapes
should be considered as markers in the prediction of MCI
conversion to AD together with the CSF markers.
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